The COVID-19 Vaccine (Vero Cell), Inactivated, CoronaVac® was approved for Conditional marketing authorization or emergency use approval of the COVID-19 Vaccine (Vero Cell), Inactivated, CoronaVac®, granted in dozens of countries including China, Chile, Turkey, Brazil, and Indonesia
Commercially launched the live attenuated Varicella Live Vaccine, Live
Commercially launched the Influenza Inactivated Vaccine (Split Virion), Inactivated, Quadrivalent
Commercially launched the 23-valent Pneumococcal Polysaccharide Vaccine
Initiated a project named, "Anti COVID-19 Action" , to develop an inactivated COVID-19 vaccine,
CoronaVac®, which was. To be the first one batch of COVID-19 vaccines in China to be approved for emergency use
The company's fourth production site base - Beijing Daxing Campus- was put into use
Sinovac (Singapore) Ltd. was incorporationincorporated
Sinovac’s Inactivated Hepatitis A vaccine, Healive®, passed the pre-qualification assessment by the WHO, making it’s the only hepatitis A vaccine in China that passed the pre-qualification assessment by WHOto reach this milestone.
Commercially launched the world's first class I1 new drug for preventative biological products - Enterovirus Type 71 Inactivated Vaccine (Vero Cell) , Inactivated, Inlive®
Commercially launched an live attenuated Mumps live Vaccine
Sinovac (Dalian) Vaccine Technology Co., Ltd. was incorporatedincorporatedfounded;
Construction began on tthe new Changping new vaccine industrial base
The world’s first H1N1 Influenza A Inactivated Vaccine (Split Virion), Inactivated, Panfu.1®, was approved to producefor production and started mass ive vaccination was started started.
Sinovac stepped into the international market, with itsSinovac international market initated; Healive® vaccine exported to Mongolia； and the and Anflu®, vaccine exported to the Philippines;
Sinovac Life Sciences Sciences Co., ., Ltd. was incorporated;
Sinovac Holdings was moved to the NASDAQ Global Select Market
China’s first Pandemic Influenza Vaccine (Inactivated, Adjuvanted), PanFlu®, was approved to be produced for government stockpiling.
Sinovac Biotech (Hong Kong) Ltd. was incorporated.
Sinovac became the first manufacturer enterprise from a developing country to join the IFPMA.
Commercially Launched launched an Influenza Inactivated Vaccine (Split Virion), Inactivated, Anflu®
Commercially Launched launched China's first and the world's second Hepatitis A and Hepatitis B Combined Vaccine, Bilive®
Resulting unblindingRevealed The of the results of the phase I clinical research trailsresult study onf the world's of the first SARS inactivated Vvaccine, inactivated is unblinded
Initiation ofed the development research of on a pandemic influenza vaccine to protect against human infection from the highly pathogenic avian influenza virus (H5N1)
Sinovac shares werewas listed on the American Stock Exchange (AMEX)
Initiation ofed the development of an inactivated SARS Vaccine R&D program , and completed ion of pre-clinical studyresearch
Sinovac was listed in US
Commercially launched China’s first inactivated hepatitis A vaccine, Healive®, was commercially launched
Sinovac Biotech Co., Ltd. incorporatedwas founded
A “new drug certificate” was obtained for tTheIts Iiinactivated Hhhepatitis A vaccine was certificated as a new drug
Cooperated with the National Institute for the Control of Pharmaceutical and Biological Products to initiate the development of an inactivated Hepatitis A vaccine
Developed China’s first Hepatitis A enzyme-linked diagnostic reagent
Successfully isolated the TZ84 strain of the hepatitis A virus
Conducted an investigation into endemic areas with endemic hepatitis A